{"name":"Cerevance Beta, Inc.","slug":"cerevance-beta-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQMnZXNmsweU0zY1hhVk15eXRtZlAxWVhnQzA0SGVza1VHV3JVVzd3dHh6UWc0YU1tUjIxM0tLNDYxeHRvczdBR01zcmxpR25haGFaMTN6cS1kYzRHQ0Nyakw4X3NWVnBsZF9nNXFKN2NLM1g0MTdwWVFCMThLSVJOU21HV2hNWDRMS2g3RnJOblpTOTNHRU9DQkZtNnRoNEhiTElqaVFCZEhLVlFtS2ttdnM0dldaYmxuaUZyaGM3ektfSHdHal9aVkZhNmNSMzhORm9SMFVwMG1lMFhZRU1ZcWdpdlFObkdyYm84WDc0VjNJLWNtNE5qUGF3?oc=5","date":"2025-05-29","type":"regulatory","source":"PR Newswire","summary":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight - PR Newswire","headline":"INBRIJA Positioned for Stronger Market Penetration as Demand Grows for Inhaled Parkinson's Therapy| DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORV9rNzJNLWJ2WWxXTktiM05GaUE3a3k2Z3dub2hlREZWUGdvVDBNT05Xbmh2U1lUWmFfMzFHaHhJY1Rhb2FmNWx6M3hwNW54YXQxeEZ3UFE1U1AyNy1JUVM4TTVLYVdEdGpkenJpaUZ1a2tyLUh6LWhMRGJjZVF5LUtVWmRPVTBVaXNKNXpTU2dNck5OaE1raVRYd1dwUXh4alRsemtURkZJc0VlUE1SdmpSYVpsZE16eXFuV3llaURzSVJ3MUtRYy1yYWFEaFJKZG42YndSbmhOV0U?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight - PR Newswire","headline":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQdzNUZFRCTVhoSUllbW1XakkxWEZseVhpUVpUMldwNkhMSGZSR0EtYlFZdTREMG5hVUpPWDRwMEJfNW94eU1JbzdXeUVubkl5MnZtUFZLWTMzME9kbW9yTnFkVWdtQjJLRjVBdWtxeHMyTDh6Rk5peXNDaHUxSWthampFTVdfbVowNExVUmFvMnpOYjlsVGs1MmpLbHlvbW56RmlBOE5zVnZzY2VVYnlrU2dST0k5RmVGTU9GdVI5eDBDd1lURE1vU2tBV1ZuR1lwUzNwanBWS29uNW5qZVVaVGtvT1VkdXVkU2swQlQxQVgtNWVkdk95UEVJUVRycDAzNk9mSjl0b1RZaXV1cGxzSlg1bUE3Q3FTWmVLVFgzWW9YQ2M5amNaeQ?oc=5","date":"2025-02-13","type":"trial","source":"GlobeNewswire","summary":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire","headline":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNZllSd2g1blhpVWJucGRwZ2ZFMTQ2Y2FPZ0E1NHppVzU5S1I0STBWZ1ZjblFxMXBXVHVXelhXTDF3OWd1MnlPR1ExMEFhYV9rbC02OUw3UjJRM1lJV2lyVUNORFFzR3NCZWxCeUVsYXdLTVR1UzIzQ1JQdnNvdGZaYVhqMHVOYWFSNFh5M3RXWVI4NlBRX0JKY29FbldKSUVoRk9XZU1VZXJQNFlfNjFBV2dORGVOQk9VUkdoS1JuQkd2SWcwX3RlbnUtZl9rbG9NZkNScFpGZkx6RzBGNEpsbjluQmlOejU2ZGhRSXpnS3Q0WUpQWTN2MGNUTkREbTUyQXJXdGJpY1I5YjV6N2VyenFLelZ2U2RzZ0RnSjEzQWlJbXNIRFhZcHREX0hweXNO?oc=5","date":"2024-12-12","type":"pipeline","source":"GlobeNewswire","summary":"Parkinson's Disease Market is Expected to Showcase a - GlobeNewswire","headline":"Parkinson's Disease Market is Expected to Showcase a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxQUGx5Nnc2U2laS20yUFdZSFh3ekpCN2Y2aUI0M1pPajZnYVlySy1RTktGRzBEUmlGay04c0hWUDN0Tm9WWGF4dVMxdlpEX2FMLWhVSHd3N1c4bWxuMkRyck91Z1hSeVBmS2pkQ0U2dnpDb2VXVF9yNERJUTBIZEFBY2tyNUpVWm5wdmNVQUdqbzc1S0pNUmlRQ2tKWFNuTjJyUWtVblRpaEtSV3lIWE1ZSFZSaFRWMi05NEk3VE9MLUZ4U2VkSDN4UTlwQkZxeXJsZnVIM0ZxWjh4STZfM2puRDhGZTI1Rmg5YlFrVHk1WnZxaGVldjNpTDJKZUxsRVEyX1FFeVVnQXdveTJ1RHdBalBxcTN0LUYyelhINXhHLWtaMG4wSnFBSnd4Q0dJbTJsckVvN2NCbEw4VG1lSndldTlEajZDOTZTb2hBQm1ybGxMU1pwSmI1RWkxd192aldTNGc?oc=5","date":"2024-10-09","type":"trial","source":"PR Newswire","summary":"Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - PR New","headline":"Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Hori","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOVk8yNlBRdDhPT3JXd2hZTTlwLUhuXzRvYlhhWFJudUpXaWlRbWl4WV9RbjVLVUpDVlI1TmRUaF8waHVnQUl0UXN6Y1Z4NGJaQTJSTHR5VzJ5VDJ0TzlCUWpTR0xGWjg5UVhtMG8wNUplTVR5LTZ6b2k1bno0MXEzWnNObDdOdE1xWGRVaGtvUkRLOTF1TjhZWkJCdnMtTmtmTjlzSVd4bkpheEJzajdoRkxETnVmZmhQRkRFUExhV2F3dmJsUWVMd3BZREhEcXdrWFg1cVFTZWMtTk9vdmhMSlZSRGtLQVBjVllfQTlXYnhnY3RkRkJJZS1hSlVWWm1Kb3FzcGRLajljSlUxWmwydXhLVC1ZdWI5eGt5emp1eFhwMmIy?oc=5","date":"2024-07-22","type":"pipeline","source":"GlobeNewswire","summary":"Cell and Gene Therapy in Parkinson's Disease Market to - GlobeNewswire","headline":"Cell and Gene Therapy in Parkinson's Disease Market to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNeDdqQ05ZcVhNR3FNSGg0TnR6UHJhckRJTnhPbmdkV0xUZWhiRjdmZUREdnlhbjRsZTJVaEdwUHVBMmp5N3lMckZqVVd2ZkxWX3pYOUpqdTUwUGlFRGxpcndPd1JpeTZ1dUJEbm16RlRMTmNCdk5jODFCNG1QOFRzNi1vVm9oMUhoVFJlSkc3UlI1cVdsMWxxdzBGeTFxN2F1eVVJbURHQU04SEdRSzVsS3k1UFVLc2dmQzJyRko4RlVrNW9jTTVBeXhObWhFUTRJTEtKTy1wQVJvTGpvVklqNm5jQU9qdkNSbWJKc0FHdFZlcXMtdHotdUt6ZG9hcEluWEN6YWx5cFg4bTh2TkdJRFhMWjBTMkc0c1pNX2l1Y1daU3BicnJLRWtBdjA?oc=5","date":"2023-04-19","type":"trial","source":"PR Newswire","summary":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight - PR Newswire","headline":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Workin","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}